SearchPublisher and Institutes
You are here: Home :: Keyword index :: ret bis sol :: Risikofaktoren - RNA world 
Rituximab
Items for "Rituximab"
The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders
Rituximab is a chimeric anti-CD20 monoclonal antibody active against normal and malignant B cells which has proven to be effective in the therapy of CD-20 positive lymphomas...
Keywords: Rituximab, inhibitor, coagulation disorders
08/2006 | Thrombosis and Haemostasis, SchattauerAddition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia
Treatment of relapsed or refractory autoimmune mediated haemolytic syndromes, such as autoimmune haemolytic anaemia (AIHA) and thrombotic thrombocytopenic purpura (TTP), represents a therapeutic challenge...
Keywords: Rituximab, TTP, AIHA
00/0000 | Thrombosis and Haemostasis, SchattauerPreparation, quality control and biodistribution studies of [67Ga]-DOTA-anti-CD20
Rituximab was successively labeled with [ 67Ga]-gallium chloride. The macrocyclic bifunctional chelating agent, N-succinimidyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA-NHS) was prepared at 25 °C using DOTA, N-hydroxy succinimide (NHS) in CH2Cl2...
Keywords: Rituximab, Gallium-67, Radiolabeling, Quality Control, DOTA
03/2008 | Radiochimica Acta, Oldenbourg Wissenschaftsverlag